| Schneider, Eric |
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). |
|
|
| Recruiting | 2 | 246 | US | Active Comparator CT1812, Placebo Comparator | Cognition Therapeutics | Age-Related Macular Degeneration | 07/27 | 08/27 | | |
NCT05345769: Safety and Efficacy of AM712 in Patients with NAMD |
|
|
| Completed | 1 | 21 | US | AM712(ASKG712) | AffaMed Therapeutics Limited | Neovascular Age-related Macular Degeneration | 11/24 | 11/24 | | |
NCT05202587: The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT |
|
|
| Completed | N/A | 386 | US | | Notal Vision Inc. | Neovascular Age-related Macular Degeneration | 01/23 | 01/23 | | |
| Busbee, Brandon G |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
